Vedlagt fremsendes meddelelse om fejl i indre værdi (NAV) for afdelinger og andelsklasser i Investeringsforeningen Maj Invest.
Ved spørgsmål er I velkomne til at kontakte trading@wealthfundpartners.dk.
Attachment
Author: Ravi Shankar
NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) — Peloton Interactive, Inc. (Nasdaq: PTON) today announced that the Company’s Chief Financial Officer, Sid Thacker, will participate in a fireside chat at the BNP Paribas Outdoor & Sports Conference on Wednesday, November 18, 2026, at 1 PM ET.
The live webcast and replay can be accessed in the Events section of the Company’s Investor Relations website: https://investor.onepeloton.com/news-and-events/events.
About Peloton
Peloton (NASDAQ: PTON) provides Members with world-class equipment, ground-breaking software, expert human instruction, and the world’s most supportive fitness community. Founded in 2012 and headquartered in New York City, Peloton has millions of Members across the US, UK, Canada, Germany, Australia, and Austria. For more information, visit www.onepeloton.com.
Investor Relations Contact:
investor@onepeloton.com
– Assets Under Management (“AuM”) Increased 5.0% Year-over-Year to $31.4 Billion –
– Increased Net Income to $2.6 Million from net income of $1.8 million in the Prior Year Period –
– Increased EBITDA[*] to $4.7 Million from $2.7 Million in the Prior Year Period –
– Increased Total Revenue to $50.6 million from $46.2 million in prior year period –
NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) — Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the third quarter and nine months ended September 30, 2026.
“Our third quarter results underscore Binah’s momentum in accelerating its growth in wealth management by leveraging our differentiated platform,” stated Craig Gould, Chief Executive Officer of Binah Capital. “Our continued progress this quarter is visible in the improved performance across all our key metrics on a year over year basis, particularly total revenue growth, higher net income and EBITDA and increased assets under management. We are very pleased with the solid operational resilience that our teams demonstrated as they effectively address customer needs, and we remain focused on taking advantage of additional opportunities to bolster our growth this year.”
Third Quarter 2026 Key Highlights
- Total advisory and brokerage assets under management as of September 30, 2026, grew 5.0% year-over-year to $31.4 billion, compared to $29.9 billion in last year’s third quarter.
- Total revenue was approximately $50.6 million, a 9.4% increase from $46.2 million in the same period in 2025.
- GAAP net income rose to $2.6 million, a 44.4% increase compared to GAAP net income of $1.8 million in the third quarter of 2025.
- Gross profit* was $10.0 million, an increase of 11.1% compared to $9.0 million in the prior-year period.
- GAAP diluted EPS was $0.13 compared to a GAAP net income per share of $0.08 in the prior year quarter, up 62.5%.
- EBITDA* of $4.7 million grew 74.1% as compared to EBITDA of $2.7 million in the prior year quarter, driven by the increase in GAAP net income.
- Adjusted EBITDA* of $4.9 million increased 69.0% compared to $2.9 million in the prior year quarter.
* Non-GAAP Financial Measures.Gross profit is a non-GAAP financial measure defined as total revenue net of commissions paid to financial advisors and registered representatives and other fees that generate the revenue.. EBITDA and Adjusted EBITDA are non-GAAP financial measures defined as net income (loss) adjusted for depreciation expense, amortization expense, interest expense, share-based compensation and income tax. See the section captioned “Non-GAAP Financial Measures” below for a detailed description and reconciliation of such non-GAAP financial measures to their most directly comparable GAAP financial measures, as required by Regulation G.
Liquidity and Capital
The Company had cash and cash equivalents of $13.2 million and outstanding long-term debt of $16.7 million as of September 30, 2026.
About Binah Capital Group
Binah Capital Group (“Binah Capital”, “Binah” or the “Company”), is a financial services enterprise that owns and operates a network of industry-leading firms that empower independent financial advisors. Binah specializes in delivering value through its innovative hybrid-friendly model, making it an optimal platform for RIAs navigating today’s complex financial landscape. Binah’s portfolio companies are built to help advisors run, manage, and execute commission-based business seamlessly while providing best in class resources to support their advisory practice. We don’t just offer tools—we cultivate partnerships. Binah Capital Group stands alongside RIAs as a trusted ally, delivering the structure, flexibility, and cutting-edge solutions they need to succeed in an increasingly competitive marketplace.
For more information, please visit: www.binahcap.com.
Contact:
Binah Capital Investor Relations
Mary T. Conway
Conway Communications
mtconway@conwaycommsir.com
Binah Capital Media Relations
Donald Cutler or Lorene Yue
Haven Tower Group
(424) 317-4864 or (424) 317-4854
binah@haventower.com
Non-GAAP Financial Measures
EBITDA is a non-GAAP financial measure defined as net income plus interest expense, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA, a non-GAAP measure, plus share-based compensation costs. The Company presents EBITDA and Adjusted EBITDA because management believes that it can be a useful financial metric in understanding the Company’s earnings from operations. EBITDA and Adjusted EBITDA are not measures of the Company’s financial performance under GAAP and should not be considered as an alternative to net income or any other performance measure derived in accordance with GAAP. Additionally, Adjusted EBITDA is used in connection with the Company’s credit agreements, specifically in the calculation of financial-related covenants.
Gross profit is a non-GAAP financial measure defined as total revenue less commissions paid to financial advisors and registered representatives and other fees that generate the revenue. We consider our gross profit amounts to be non-GAAP financial measures that may not be comparable to those of others in our industry. We believe that gross profit amounts can provide investors with useful insight into our core operating performance before other costs that are general and administrative in nature.
A reconciliation of our non-GAAP financial measures to their most directly comparable GAAP financial measures appears below in the footnotes to the table of our key operating, business and financial metrics.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and factors that could cause actual results to differ materially from such statements, many of which are outside the control of Binah. Forward-looking statements include, but are not limited to statements regarding: Binah’s financial and operational outlook; Binah’s operational and financial strategies, including planned growth initiatives and the benefits thereof, Binah’s ability to successfully effect those strategies, and the expected results therefrom. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “expect,” ”intend,” “anticipate,” “goals,” “prospects,” “will,” “would,” “will continue,” “will likely result,” and similar expressions (including the negative versions of such words or expressions).
While Binah believes that the assumptions concerning future events are reasonable, it cautions that there are inherent difficulties in predicting certain important factors that could impact the future performance or results of its business. The factors that could cause results to differ materially from those indicated by such forward-looking statements include, but are not limited to: our ability to comply with supervisory and regulatory compliance obligations, the risk we may be held liable for misconduct by our advisors; poor performance of our investment products and services; our ability to effectively maintain and enhance our brand and reputation; our ability to expand and retain our customer base; our future capital requirements and sources and uses of cash; the risk that an increase in government regulation of the industries and markets in which we operate could negatively impact our business; the impact of worldwide and regional political, military or economic conditions, including declines in foreign currencies in relation to the value of the U.S. dollar, hyperinflation, devaluation and significant political or civil disturbances in international markets; and the effectiveness of Binah’s control environment, including the identification of control deficiencies.
These forward-looking statements are also affected by the risk factors, forward-looking statements and challenges and uncertainties set forth in documents filed by Binah with the U.S. Securities and Exchange Commission from time to time, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and subsequent periodic reports. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Binah cautions you not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Binah assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Binah does not give any assurance that it will achieve its expectations.
BINAH CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION
SEPTEMBER 30, 2026 AND DECEMBER 31, 2025
(in thousands, except per share amounts)
| Unaudited | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Assets: | ||||||||
| Cash, cash equivalents and restricted cash | $ | 13,242 | $ | 10,716 | ||||
| Receivables, net: | ||||||||
| Commission receivable | 11,001 | 10,441 | ||||||
| Due from clearing broker | 637 | 707 | ||||||
| Other | 1,177 | 1,261 | ||||||
| Property and equipment, net | 242 | 342 | ||||||
| Right of use assets | 3,125 | 3,097 | ||||||
| Intangible assets, net | 408 | 671 | ||||||
| Goodwill | 39,839 | 39,839 | ||||||
| Other assets | 3,459 | 3,141 | ||||||
| TOTAL ASSETS | $ | 73,130 | $ | 70,215 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Liabilities: | ||||||||
| Accounts payable, accrued expenses and other liabilities | $ | 11,473 | $ | 13,103 | ||||
| Commissions payable | 13,377 | 12,632 | ||||||
| Operating lease liabilities | 3,237 | 3,221 | ||||||
| Notes payable, net of unamortized debt issuance costs of $480 and $590 as of September 30, 2026 and December 31, 2025, respectively | 16,267 | 17,679 | ||||||
| Promissory notes-affiliates | 5,313 | 5,313 | ||||||
| TOTAL LIABILITIES | 49,667 | 51,948 | ||||||
| Mezzanine Equity: | ||||||||
| Redeemable Series A Convertible Preferred Stock, par value $0.0001, 2,000,000 shares authorized, 1,681,000 and 1,626,000 shares outstanding at September 30, 2026 and December 31, 2025, respectively | 16,229 | 15,668 | ||||||
| Stockholders’ Equity: | ||||||||
| Series B Convertible Preferred Stock, par value $0.0001, 500,000 shares authorized, 150,000 shares outstanding at September 30, 2026 and December 31, 2025 | 1,500 | 1,500 | ||||||
| Common stock, $0.0001 par value, 55,000,000 authorized, 17,060,131 and 16,716,000 issued and outstanding at September 30, 2026 and December 31, 2025, respectively | — | — | ||||||
| Additional paid-in-capital | 23,221 | 23,709 | ||||||
| Accumulated deficit | (17,612) | (22,496) | ||||||
| Accumulated other comprehensive income (loss) | 125 | (114) | ||||||
| Total Stockholders’ Equity and Mezzanine Equity | 23,463 | 18,267 | ||||||
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY | $ | 73,130 | $ | 70,215 | ||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
BINAH CAPITAL GROUP, INC .
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(in thousands, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||
| Revenues: | |||||||||||||
| Revenue from Contracts with Customers: | |||||||||||||
| Commissions | $ | 41,259 | $ | 37,370 | $ | 119,074 | $ | 112,506 | |||||
| Advisory fees | 8,145 | 7,407 | 22,805 | 20,948 | |||||||||
| Total Revenue from Contracts with Customers | 49,404 | 44,777 | 141,879 | 133,454 | |||||||||
| Interest and other income | 1,157 | 1,421 | 3,899 | 3,178 | |||||||||
| Total revenues | 50,561 | 46,198 | 145,778 | 136,632 | |||||||||
| Expenses: | |||||||||||||
| Commissions and fees | 40,567 | 37,202 | 115,736 | 110,240 | |||||||||
| Employee compensation and benefits | 4,728 | 4,679 | 14,369 | 13,956 | |||||||||
| Rent and occupancy | 291 | 286 | 841 | 857 | |||||||||
| Professional fees | 138 | 558 | 1,118 | 1,807 | |||||||||
| Technology fees | 776 | 751 | 2,370 | 2,194 | |||||||||
| Interest | 507 | 534 | 1,542 | 1,643 | |||||||||
| Depreciation and amortization | 187 | 167 | 457 | 537 | |||||||||
| Other | (679) | 71 | 2,218 | 2,551 | |||||||||
| Total expenses | 46,515 | 44,248 | 138,651 | 133,785 | |||||||||
| Income before provision for income taxes | 4,046 | 1,950 | 7,127 | 2,847 | |||||||||
| Provision for income taxes | 1,400 | 190 | 2,242 | 706 | |||||||||
| Net income | $ | 2,646 | $ | 1,760 | $ | 4,885 | $ | 2,141 | |||||
| Net income per share basic | $ | 0.13 | $ | 0.08 | $ | 0.22 | $ | 0.06 | |||||
| Net income per share diluted | $ | 0.13 | $ | 0.08 | $ | 0.22 | $ | 0.06 | |||||
| Weighted average shares outstanding: basic | 17,060 | 16,709 | 16,875 | 16,638 | |||||||||
| Weighted average shares outstanding: diluted | 17,060 | 16,720 | 16,875 | 16,921 | |||||||||
Non-GAAP Financial Measures: Binah Capital Group Reconciliation of GAAP revenue to gross profit and GAAP net income to EBITDA and Adjusted EBITDA
Gross profit and EBITDA are non-GAAP financial measures. Gross profit is a non-GAAP financial measure defined as total revenue net of commissions paid to financial advisors and registered representatives and other fees that generate the revenue.. EDITDA is defined as net income plus interest expense, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA, a non-GAAP measure, plus share-based compensation costs. The Company presents Gross Profit, EBITDA and Adjusted EBITDA because management believes that it can be a useful financial metric in understanding the Company’s total revenue and earnings from operations, respectively. Gross Profit, EBITDA and Adjusted EBITDA are not measures of the Company’s financial performance under GAAP and should not be considered as an alternative to total revenues, net income or any other performance measure derived in accordance with GAAP. Additionally, Adjusted EBITDA is used in connection with the Company’s credit agreements, specifically in the calculation of financial-related covenants.
A reconciliation of our non-GAAP financial measures to their most directly comparable GAAP financial measures appears below in the footnotes to the table of our key operating, business and financial metrics.
| For the three months ended September 30, | For the nine months ended September 30, | |||||||||||||||
| EBITDA Reconciliation | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net income | $ | 2.6 | $ | 1.8 | $ | 4.9 | $ | 2.1 | ||||||||
| Interest expense | 0.5 | 0.5 | 1.5 | 1.6 | ||||||||||||
| Provision for income taxes | 1.4 | 0.2 | 2.2 | 0.8 | ||||||||||||
| Depreciation and amortization | 0.2 | 0.2 | 0.5 | 0.5 | ||||||||||||
| EBITDA | 4.7 | 2.7 | 9.1 | 5.0 | ||||||||||||
| Share-based compensation | 0.2 | 0.2 | 0.7 | 0.6 | ||||||||||||
| Adjusted EBITDA | $ | 4.9 | $ | 2.9 | $ | 9.8 | $ | 5.6 | ||||||||
AlterG revenue increased 18% year-over-year to $3.6 million, driven by higher U.S. unit shipments, service revenue and average selling prices
The Company is advancing its transition of ReWalk to a capital-efficient channel-partner distribution model designed to expand patient access and support long-term revenue growth
New leadership team focused on commercial execution and advancing AI-enabled rehabilitation technologies
New peer-reviewed clinical evidence strengthens support for ReWalk’s long-term benefits and broader patient access
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Nov. 13, 2026 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
Business Update
- Continued growth of AlterG. AlterG revenue increased 18% to $3.6 million in the third quarter of 2026 compared to the third quarter of 2025, primarily reflecting higher U.S. unit shipments, together with increased service revenue and improved average selling prices. This marks the second consecutive quarter of double-digit year-over-year revenue growth for AlterG.
- ReWalk commercial transition to a channel-partner model. The Company is shifting ReWalk from direct sales to partnerships with established home and durable medical equipment providers and patient care organizations that can bring the ReWalk Personal Exoskeleton to patients across the United States. These partnerships build on the Company’s existing channels, including CorLife, its exclusive distributor for patients with workers’ compensation claims, and the pilot program the Company launched in August 2026 with Ottobock Care, a leading U.S. mobility technology patient care organization with more than 50 patient clinics nationwide. While the transition has affected the timing of ReWalk sales in the near term, the Company believes channel partnerships have the potential to significantly increase ReWalk revenue over the long term and is focused on expanding its partner network. Selling through partners on wholesale terms is also designed to reduce the Company’s operating expenses and may accelerate cash collection compared with direct sales.
- Broad reimbursement access supporting ReWalk adoption. ReWalk is covered by Medicare for eligible beneficiaries under an established fee schedule and by the three largest Medicare Advantage insurers, Aetna, Humana and UnitedHealthcare. Medicare Fee-for-Service and many national Medicare Advantage plans are authorizing ReWalk for clinically appropriate patients, and the Company believes this reimbursement infrastructure positions its channel partners to reach more eligible patients.
- Expansion of clinical evidence supporting ReWalk. In September and October 2026, the Company announced the publication of two peer-reviewed real-world studies of the ReWalk Personal Exoskeleton. The first reported improved performance of daily activities, higher satisfaction and lower pain compared with wheelchair use. The second, a long-term study, reported sustained home use over a median of 33 months with no reported falls or exoskeleton-related fractures.
- Well positioned for artificial intelligence (“AI”)-enabled rehabilitation. As robotics and AI increasingly move into physical care, the Company believes its combination of U.S. Food and Drug Administration (“FDA”)-cleared robotic products, established reimbursement infrastructure, commercial channels and installed base position it to bring AI-enabled rehabilitation technologies to patients. In addition to continued development of its upper-body exoskeleton with AI capabilities, Lifeward is exploring the addition of other AI-enabled capabilities into its product development pipeline.
“The third quarter was a transitional quarter for Lifeward, marked by continued AlterG growth as we move into the advanced stages of transitioning ReWalk to a channel-partner distribution model,” said Josh Hexter, Interim Chief Executive Officer of Lifeward. “Moving away from direct sales can create timing gaps in the near term, but we believe partnering with established providers that already reach patients nationwide is the right path to significantly expand access to ReWalk and accelerate revenue growth over the long term.”
Third Quarter 2026 Financial Results
Revenue was $5.4 million in the third quarter of 2026, compared to $6.2 million in the third quarter of 2025, a decrease of $0.8 million, or 12%. Revenue from AlterG products and services increased 18% to $3.6 million, primarily reflecting higher U.S. unit shipments, together with increased service revenue and improved average selling prices. Revenue from the sale of ReWalk Personal exoskeletons was $1.7 million, compared to $3.0 million in the third quarter of 2025, reflecting lower U.S. sales as the Company transitions ReWalk to a channel-partner distribution model, as well as lower revenues in Europe.
Gross margin was 27.4% during the third quarter of 2026, compared to 43.7% in the third quarter of 2025. The year-over-year decrease was primarily attributable to adverse foreign exchange rate fluctuations, higher freight costs and tariffs and revenue sharing expense arising from the Company’s March 2026 acquisition of Oratech Pharmaceuticals Ltd. from Oramed Pharmaceuticals Inc. (the “Oratech Acquisition”), under which the Company agreed to make quarterly payments to Oramed based on sales of ReWalk Personal Exoskeleton products and related extended warranties. On a non-GAAP basis, adjusted gross margin was 27.5% during the third quarter of 2026, compared to 43.7% in the prior-year quarter.
Total operating expenses in the third quarter of 2026 were $7.5 million, compared to $5.9 million in the third quarter of 2025. The increase was primarily attributable to approximately $0.5 million of clinical trial and contract research organization service costs related to the Oratech clinical trial, higher development costs related to the AlterG product improvement project and the upper-body exoskeleton technology, higher spending on trade shows and digital marketing, and restructuring expenses. On a non-GAAP basis, which excludes the items listed in the attached non-GAAP reconciliation table, adjusted operating expenses were $7.0 million in the third quarter of 2026, compared to $5.7 million in the third quarter of 2025, with the year-over-year change primarily attributable to the Oratech clinical trial costs and product development activities.
Operating loss in the third quarter of 2026 was $6.0 million, compared to $3.1 million in the third quarter of 2025. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted operating loss was $5.5 million in the third quarter of 2026, compared to $3.0 million in the third quarter of 2025.
Net loss was $5.1 million, or $1.32 per share, in the third quarter of 2026, compared to $3.2 million, or $2.37 per share, in the third quarter of 2025. The increase primarily reflects a higher operating loss partially offset by net financial income of $0.9 million in the third quarter of 2026, which includes non-cash fair value changes in warrant and derivative liabilities as well as interest expense related to the Company’s convertible notes. On a non-GAAP basis, which excludes the items in the attached non-GAAP reconciliation table, adjusted net loss was $5.5 million, or $1.44 per share, in the third quarter of 2026, compared to $3.0 million, or $2.24 per share, in the third quarter of 2025.
Balance Sheet
Unrestricted cash and cash equivalents were $4.5 million as of September 30, 2026, compared to $2.2 million as of December 31, 2025.
About Lifeward
Lifeward is a global innovator focused on advancing medical technologies and biomedical solutions that improve lives. The Company’s established portfolio includes market-leading neurorehabilitation technologies such as the ReWalk® Exoskeleton, AlterG® Anti-Gravity systems, and MyoCycle® FES System. These solutions span the continuum of care in physical rehabilitation and recovery, deploying the most advanced robotics and AI technologies to restore full health and quality of life to a broadening patient population. The Company is now executing a strategic evolution into a diversified biomedical company, expanding beyond rehabilitation and into high-value therapeutic platforms. This includes its Protein Oral Delivery (POD™) platform, designed to enable oral delivery of biologic drugs, with lead candidate ORMD-0801 (oral insulin) targeting a large and underserved diabetes market.
Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward mission and product portfolio, please visit GoLifeward.com.
Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Use of Non-GAAP Financial Measures
In addition to financial results prepared in accordance with U.S. GAAP, this earnings release includes certain non-GAAP financial measures, including adjusted gross profit, adjusted gross margin, adjusted operating expenses, adjusted operating loss, adjusted net loss and adjusted net loss per share. These measures exclude certain items, as applicable, including stock-based compensation expense, restructuring expense, acquired in-process research and development expense, transaction-related expenses, amortization of acquired intangible assets, non-cash debt-discount amortization, changes in the fair value of warrant and derivative liabilities, acquisition-related income or expense and other items reflected in the reconciliations below.
Management believes the non-GAAP financial information provided in this release is useful to investors in understanding and assessing the Company’s ongoing operations. Management uses both GAAP and non-GAAP information to evaluate and operate the business internally and believes it is useful to provide this information to investors. Non-GAAP financial measures should not be considered in isolation or as a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The GAAP results and reconciliations of the non-GAAP measures to the most directly comparable GAAP measures are provided below.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding the Company’s future performance and other statements that are not statements of historical fact and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. For example, when the Company discusses the transition of ReWalk to a channel-partner distribution model and its potential to increase ReWalk revenue, the anticipated growth of AlterG, the development and potential benefits of AI-enabled capabilities and products, reimbursement coverage, the expected benefits of the channel-partner model, including the potential for lower operating expenses and faster cash collection, demand for rehabilitation technologies, and the Company’s strategy, priorities and long-term growth, it is using forward-looking statements. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. Important factors that could cause the Company’s actual results to differ materially from those indicated in the forward-looking statements include, among others, risks and uncertainties relating to: the integration of Oratech and realization of the anticipated benefits of the Oratech acquisition; the development, timing, results and regulatory approval of ORMD-0801 and the Company’s other product and clinical-development programs; the sufficiency of the Company’s capital resources, its ability to obtain additional financing and continue as a going concern, and potential dilution resulting from its outstanding convertible securities and warrants; commercialization, market acceptance, reimbursement and sales growth for the Company’s products; the Company’s reliance on third-party payors, manufacturers, suppliers and distributors, and its customer and trade-receivables concentration; recent management and Board transitions; regulatory compliance, product defects and adverse events; intellectual-property protection; cybersecurity; and legislative, regulatory, political and economic developments, as well as other factors discussed under the heading “Risk Factors” in the Company’s annual report on Form 10-K, for the year ended December 31, 2025, in Part II, Item 1A of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and in other documents subsequently filed with, or furnished to, the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Contact
Ronen Tsimerman
Chief Financial Officer
Lifeward
E: media@golifeward.com
E: ir@golifeward.com
Lifeward Ltd. and subsidiaries
| Condensed Consolidated Statements of Operations | ||||||||||||
| (Unaudited) | ||||||||||||
| (In thousands, except share and per share data) | ||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Revenue | $5,428 | $6,195 | $15,974 | $16,953 | ||||||||
| Cost of revenues | 3,941 | 3,488 | 10,436 | 9,613 | ||||||||
| Gross profit | 1,487 | 2,707 | 5,538 | 7,340 | ||||||||
| Operating expenses: | ||||||||||||
| Research and development, net | 1,941 | 721 | 9,540 | 2,406 | ||||||||
| Sales and marketing | 3,351 | 3,168 | 10,153 | 10,790 | ||||||||
| General and administrative | 2,165 | 1,958 | 6,306 | 5,917 | ||||||||
| Impairment charges | – | – | – | 2,783 | ||||||||
| Total operating expenses | 7,457 | 5,847 | 25,999 | 21,896 | ||||||||
| Operating loss | (5,970 | ) | (3,140 | ) | (20,461 | ) | (14,556 | ) | ||||
| Financial expense (income), net | (926 | ) | 23 | 6,879 | (8 | ) | ||||||
| Loss before income taxes | (5,044 | ) | (3,163 | ) | (27,340 | ) | (14,548 | ) | ||||
| Taxes on income | 8 | 7 | 24 | 18 | ||||||||
| Net loss | $(5,052 | ) | $(3,170 | ) | $(27,364 | ) | $(14,566 | ) | ||||
| Basic net loss per ordinary share | $(1.32 | ) | $(2.37 | ) | $(9.91 | ) | $(13.87 | ) | ||||
| Weighted average number of shares used in computing net loss per ordinary share basic and diluted (*) | 3,836,950 | 1,335,117 | 2,760,466 | 1,050,290 | ||||||||
| (*) All share and per share amounts presented in this note have been retroactively adjusted to reflect the Company’s 1-for-12 reverse share split effected on February 24, 2026. | ||||||||||||
| Lifeward Ltd. and subsidiaries | ||
| Condensed Consolidated Balance Sheets | ||
| (In thousands) | ||
| (Unaudited) | (Audited) | |
| September 30, | December 31, | |
| 2026 | 2025 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $4,548 | $2,169 |
| Restricted cash | 3 | 240 |
| Clinical trial services asset | 539 | – |
| Trade receivables, net of credit losses of $209 and $192, respectively | 7,649 | 6,138 |
| Prepaid expenses and other current assets | 2,261 | 1,528 |
| Inventories | 6,697 | 5,732 |
| Total current assets | 21,697 | 15,807 |
| Restricted cash and other long term assets | 484 | 209 |
| Clinical trial services asset | 269 | – |
| Operating lease right-of-use assets | 2,441 | 1,544 |
| Property and equipment, net | 463 | 585 |
| Intangible assets | 409 | - |
| Goodwill | 4,755 | 4,755 |
| Total assets | $30,518 | $22,900 |
| Liabilities and equity | ||
| Current liabilities | ||
| Trade payables | $5,838 | $5,590 |
| Current maturities of operating leases | 762 | 425 |
| Convertible promissory note | – | 2,803 |
| Other current liabilities | 4,255 | 3,221 |
| Total current liabilities | 10,855 | 12,039 |
| Non-current operating leases | 1,712 | 1,159 |
| Convertible promissory notes, net | 7,133 | – |
| Warrants liability | 1,988 | – |
| Other long-term liabilities | 1,563 | 1,294 |
| Shareholders’ equity | 7,267 | 8,408 |
| Total liabilities and equity | $30,518 | $22,900 |
| Lifeward Ltd. and subsidiaries | ||||||
| Condensed Consolidated Statements of Cash Flows | ||||||
| (Unaudited) | ||||||
| (In thousands) | ||||||
| Nine Months Ended | ||||||
| September 30, | ||||||
| 2026 | 2025 | |||||
| Net cash used in operating activities | $(16,064 | ) | $(13,271 | ) | ||
| Net cash used in investing activities | (28 | ) | (5 | ) | ||
| Net cash provided by financing activities | 18,502 | 8,425 | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (9 | ) | 103 | |||
| Increase (decrease) in cash, cash equivalents, and restricted cash | 2,401 | (4,748 | ) | |||
| Cash, cash equivalents, and restricted cash at beginning of period | 2,579 | 7,108 | ||||
| Cash, cash equivalents, and restricted cash at end of period | $4,980 | $2,360 | ||||
| Lifeward Ltd. and subsidiaries | ||||
| (Unaudited) | ||||
| (In thousand) | ||||
| Three Months Ended | Nine Months Ended | |||
| September 30, | September 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| Revenues based on customer’s location: | ||||
| United States | $3,270 | $4,044 | $9,692 | $10,263 |
| Europe | 613 | 627 | 2,370 | 2,100 |
| Germany | 1,003 | 1,192 | 2,835 | 3,209 |
| Asia-Pacific | 298 | 103 | 586 | 269 |
| Rest of the world | 244 | 229 | 491 | 1,112 |
| Total revenues | $5,428 | $6,195 | $15,974 | $16,953 |
| Lifeward Ltd. and subsidiaries | ||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures | ||||||||||||
| (Unaudited) | ||||||||||||
| (In thousands) | ||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| Dollars in thousands, except per share data | 2026 | 2025 | 2026 | 2025 | ||||||||
| GAAP net loss | $(5,052 | ) | $(3,170 | ) | $(27,364 | ) | $(14,566 | ) | ||||
| Adjustments: | ||||||||||||
| Amortization of intangible assets | 23 | – | 33 | – | ||||||||
| Non-cash acquired in-process R&D expense | – | – | 4,947 | – | ||||||||
| Oramed transaction-related expenses | – | – | 619 | – | ||||||||
| Other income related to the settlement of the post closing statement for the acquisition of AlterG | – | – | (142 | ) | – | |||||||
| Restructuring | 300 | – | 544 | 700 | ||||||||
| Remeasurement of earnout liability | – | – | – | (608 | ) | |||||||
| Impairment charges | – | – | – | 2,783 | ||||||||
| Stock-based compensation expenses | 103 | 174 | 542 | 576 | ||||||||
| Non-cash amortization of debt discount associated with the convertible notes and warrants | 457 | – | 1,415 | – | ||||||||
| Fair value remeasurement of warrant and derivative liabilities | (1,347 | ) | – | 5,041 | – | |||||||
| Non-GAAP net loss | $(5,516 | ) | $(2,996 | ) | $(14,365 | ) | $(11,115 | ) | ||||
| Weighted average shares used in computing net loss per share (*) | 3,836,950 | 1,335,117 | 2,760,466 | 1,050,290 | ||||||||
| Non-GAAP net loss per share | $(1.44 | ) | $(2.24 | ) | $(5.20 | ) | $(10.58 | ) | ||||
(*) All share and per share amounts presented in this note have been retroactively adjusted to reflect the Company’s 1-for-12 reverse share split effected on February 24, 2026.
| Lifeward Ltd. and subsidiaries | ||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures | ||||||||||||
| (Unaudited) | ||||||||||||
| (In thousands) | ||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue | ||||
| GAAP operating loss | $(5,970) | (110.0)% | $(3,140) | (50.7)% | $(20,461) | (128.1)% | $(14,556) | (85.9)% | ||||
| Amortization of intangible assets | 23 | 0.4% | - | - | 33 | 0.2% | - | - | ||||
| Non-cash acquired in-process R&D expense | - | - | - | - | 4,947 | 31.0% | - | - | ||||
| Oramed transaction-related expenses | - | - | - | - | 619 | 3.9% | - | - | ||||
| Other income related to the settlement of the post closing statement for the acquisition of AlterG | - | - | - | - | (142) | (0.9)% | - | - | ||||
| Restructuring | 300 | 5.5% | - | - | 544 | 3.4% | 700 | 4.1% | ||||
| Remeasurement of earnout liability | - | - | - | - | - | - | (608) | (3.6)% | ||||
| Impairment charges | - | - | - | - | - | - | 2,783 | 16.4% | ||||
| Stock-based compensation expenses | 103 | 1.9% | 174 | 2.8% | 542 | 3.4% | 576 | 3.4% | ||||
| Non-GAAP operating loss | $(5,544) | (102.2)% | $(2,966) | (47.9)% | $(13,918) | (87.1)% | $(11,105) | (65.6)% | ||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
| 2026 | 2025 | 2026 | 2025 | |||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue |
| GAAP gross profit | $1,487 | 27.4% | $2,707 | 43.7% | $5,538 | 34.7% | $7,340 | 43.3% |
| Adjustments: | ||||||||
| Stock-based compensation expenses | 4 | 0.1% | 3 | 0.0% | 10 | 0.1% | 10 | 0.1% |
| Non-GAAP gross profit | $1,491 | 27.5% | $2,710 | 43.7% | $5,548 | 34.8% | $7,350 | 43.4% |
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue | ||||||||
| GAAP research & development | $1,941 | 35.8% | $721 | 11.6% | $9,540 | 59.7% | $2,406 | 14.2% | ||||||||
| Adjustments: | ||||||||||||||||
| Amortization of intangible assets | (23) | (0.4)% | - | - | (33) | (0.2)% | - | - | ||||||||
| Non-cash acquired in-process R&D expense | - | - | - | - | (4,947) | (31.0)% | - | - | ||||||||
| Stock-based compensation expenses | (30) | (0.6)% | (32) | (0.5)% | (104) | (0.7)% | (105) | (0.6)% | ||||||||
| Non-GAAP research & development | $1,888 | 34.8% | $689 | 11.1% | $4,456 | 27.8% | $2,301 | 13.6% | ||||||||
| Lifeward Ltd. and subsidiaries | ||||||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue | ||||||||
| GAAP sales & marketing | $3,351 | 61.7% | $3,168 | 51.1% | $10,153 | 63.6% | $10,790 | 63.6% | ||||||||
| Adjustments: | ||||||||||||||||
| Restructuring | - | - | - | - | (244) | (1.5)% | (277) | (1.6)% | ||||||||
| Stock-based compensation expenses | (36) | (0.7)% | (65) | (1.0)% | (99) | (0.6)% | (203) | (1.2)% | ||||||||
| Non-GAAP sales & marketing | $3,315 | 61.0% | $3,103 | 50.1% | $9,810 | 61.5% | $10,310 | 60.8% | ||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Dollars in thousands | $ | % of revenue | $ | % of revenue | $ | % of revenue | $ | % of revenue | ||||||||
| GAAP general & administrative | $2,165 | 39.9% | $1,958 | 31.6% | $6,306 | 39.5% | $5,917 | 34.9% | ||||||||
| Adjustments: | ||||||||||||||||
| Other income related to the settlement of the post closing statement for the acquisition of AlterG | - | - | - | - | 142 | 0.9 | - | - | ||||||||
| Oramed transaction-related expenses | - | - | - | - | (619) | (3.9)% | - | - | ||||||||
| Restructuring | (300) | (5.5)% | - | - | (300) | (1.9)% | (423) | (2.5)% | ||||||||
| Remeasurement of earnout liability | - | - | - | - | - | - | 608 | 3.6% | ||||||||
| Stock-based compensation expenses | (33) | (0.6)% | (74) | (1.2)% | (329) | (2.1)% | (258) | (1.5)% | ||||||||
| Non-GAAP general & administrative | $1,832 | 33.8% | $1,884 | 30.4% | $5,200 | 32.5% | $5,844 | 34.5% | ||||||||
Company makes scheduled payment to Eastern Standard sellers, continues to reduce debt and works to close acquisitions
WILMINGTON, Del., Nov. 13, 2026 (GLOBE NEWSWIRE) — Onfolio Holdings, Inc. (Nasdaq: ONFO, ONFOW) (OTC: ONFOP) (the “Company” or “Onfolio”), an owner-operator of cash-generative online businesses, today provided a corporate update.
Stockholders’ equity
The Company’s stockholders’ equity is now above the $2.5 million minimum required for continued listing on The Nasdaq Capital Market. In October, Nasdaq granted the Company an extension until November 23, 2026 to evidence compliance with this requirement. The Company will provide the required confirmation to Nasdaq, and compliance remains subject to Nasdaq’s determination.
Minimum bid price
At its special meeting on November 5, 2026, stockholders approved giving the Board authority to effect one or more reverse stock splits, if needed, to maintain compliance with Nasdaq’s $1.00 minimum bid price requirement.
Balance sheet
The Company currently has no convertible notes outstanding. Its financing facility with an institutional investor remains in place.
In October, the Company made the $450,000 initial payment due under its forbearance agreement with the sellers of Eastern Standard on schedule, funded through a sale of a portion of its digital assets. The remaining balance is payable in monthly installments through July 2027. Reducing debt remains a priority for the Company.
Acquisitions
All of the Company’s previously announced letters of intent remain in place, and the Company is finalizing additional letters of intent. The Company believes it may be able to close one or two acquisitions soon, particularly once its listing compliance is resolved. Acquisitions involve many parties and moving pieces, and timelines can change, so the Company will not provide specific target dates in future.
“We’ve spent the last few months working through the balance sheet, and it’s in a much better place,” said Onfolio CEO Dominic Wells. “Our equity is back above the Nasdaq minimum, we have no convertible notes outstanding, and we met the Eastern Standard payment on time. That puts us in a stronger position to get acquisitions closed, which is where our focus is now.”
ABOUT ONFOLIO HOLDINGS
Onfolio Holdings Inc. (Nasdaq: ONFO) is an owner-operator of cash-generative online businesses. The Company acquires and operates profitable online businesses across diverse verticals, including marketing, education, and e-commerce, with a focus on sustainable cash flow and long-term value creation. The Company uses AI across its operations to improve acquired businesses, build internal tools, and develop AI-powered products.
Visit www.onfolio.com for more information.
FORWARD-LOOKING STATEMENTS
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continues,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, Nasdaq’s determination regarding the Company’s compliance with its continued listing requirements, the Company’s ability to maintain compliance with the minimum bid price requirement, the Company’s ability to make remaining payments under its forbearance agreement, the Company’s ability to complete due diligence, negotiate definitive agreements, obtain financing and close acquisitions on expected timelines or at all, market conditions affecting the Company’s common stock, general economic and business conditions, those events and factors described by us in Item 1.A “Risk Factors” in our most recent Form 10-K and Form 10-Q; other risks to which our Company is subject; other factors beyond the Company’s control. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
INVESTOR CONTACT
investors@onfolio.com
New energy group EPSO-G (legal entity code 302826889, registered office address: Laisvės pr. 10, Vilnius, Lithuania) announces interim financial and operating results for January–September of 2026.
Key financial indicators for the first nine months of 2026:
| Key financial indicators | January-September 2026 | January-September 2025 | Change, % |
| Revenue, EUR million | 460.7 | 372.8 | 23.6 |
| EBITDA, EUR million | 87.4 | -10.1 | n/a |
| Net profit, EUR million | 54.2 | -35.2 | n/a |
| Investments in energy infrastructure, EUR million | 158.3 | 126.0 | 25.6 |
| Investments in defence industry companies, EUR million | 33.6 | 36.5 | -7.9 |
| ROE (last 12 months), % | 29.5 | -4.5 | n/a |
| Net debt, EUR million | 63.8 | 79.2 | -15.4 |
| Adjusted* EBITDA, EUR million | 68.1 | 59.9 | 13.7 |
| Adjusted* net profit, EUR million | 37.7 | 24.8 | 52.3 |
| Adjusted* ROE (last 12 months), % | 12.7 | 11.1 | n/a |
| Adjusted EBITDA (last 12 months), EUR million | 84.9 | 75.1 | 13.0 |
| Net debt-to-adjusted EBITDA (last 12 months) | 0.8 | 1.1 | n/a |
* Profitability indicators are recalculated due to temporary regulatory deviations from the regulated profitability approved by the National Energy Regulatory Council. When calculating adjusted indicators, the adjustment of revenue for previous periods, which has already been approved by the NERC decision when setting regulated prices for transmission services for the reporting period, is taken into account and the deviation between the (regulated) profitability approved by the NERC and the actual profitability for the reporting period is assessed, which will be evaluated by the NERC when setting transmission prices for future periods. Other atypical gains or losses are also eliminated when calculating the adjusted indicators.
EPSO-G group of companies consists of the holding company EPSO-G and six directly controlled subsidiaries: Amber Grid, Baltpool, Energy cells, EPSO-G Invest, Litgrid and Tetas. EPSO-G and the Group companies also hold shares in Rheinmetall Defence Lietuva, Baltic RCC OÜ and TSO Holding AS. The Ministry of Energy of the Republic of Lithuania exercises the rights and obligations of the sole shareholder of EPSO-G.
Enclosed: Integrated Interim Report for the first nine months of 2026 (management, consolidated and company financial statements) and press release.
Further information
Gediminas Petrauskas, Communications Partner at EPSO-G
Tel. +370 610 63306, email gediminas.petrauskas@epsog.lt
Attachments
Fans choose any NCAA or NAIA school, and 20% of their plan price goes to its athletic department or NIL collective
Athletic programs can launch their own branded wireless service on GrowthLine and receive 25% of each plan price
BARTLETT, Tenn., Nov. 13, 2026 (GLOBE NEWSWIRE) — SurgePays, Inc. (NASDAQ: SURG) (“SurgePays” or the “Company”), a fintech company that launches and runs wireless brands, today announced the launch of NILwireless, a wireless service that sends 20% of every monthly plan price to the college sports program the customer chooses. The school’s share is included in the plan price at no additional cost to the customer. NILwireless runs on America’s most reliable network and is built on GrowthLine, the Company’s partner operating platform.
NILwireless reaches fans and schools through two channels. Any fan can become an athletic Booster by signing up directly for NILwireless and picking their favorite NCAA or NAIA school. Every month, NILwireless sends 20% of the plan price to that school’s athletic department or NIL (Name, Image and Likeness) collective.
Plans range from $10 to $50 a month with unlimited talk and text, 5G data and roaming in the US, Canada and Mexico. Customers keep their phone and number, and a referral program gives both the customer and a referred friend 50% off a bill.
In the second channel, NILwireless is built to roll out school branded wireless services for athletic departments, NIL collectives, alumni associations and booster clubs through the Company’s GrowthLine platform. Each program that launches its own branded service receives 25% of every monthly plan price, compared with posted rates of up to 7% with other school wireless programs.
College athletics now run on capital that schools must raise every year. Under the House v. NCAA settlement, schools can pay athletes directly up to $20.5 million in 2025-26, rising to $21.58 million in 2026-27 according to the College Sports Commission. A U.S. Government Accountability Office report found that 94% of NCAA Division I athletic programs spent more than they brought in during 2023-24, and a U.S. Senate Commerce Committee report found that only 14 of 53 publicly reported Power 4 athletic departments covered their expenses in 2024-25.
“College sports fans are found in every corner of the country and are fiercely loyal to their schools. Every program is competing for talent, and fans want to help their team win,” said Brian Cox, Chief Executive Officer of SurgePays and a former Division I offensive lineman. “NILwireless lets thousands of fans become boosters with a monthly bill they already pay, and it gives every school a way to launch its own wireless brand and build dependable monthly funding and a direct connection with their most loyal fans and alumni.”
NILwireless is available now at www.nilwireless.com with additional Booster engagement features planned to launch in the near future. NILwireless is not affiliated with, sponsored by or endorsed by any school, conference, the NCAA or the NAIA. For more information, please visit www.nilwireless.com.
About SurgePays, Inc.
SurgePays, Inc. (NASDAQ: SURG) is a fintech company that launches and runs wireless brands. Through its GrowthLine platform, SurgePays provides partners with carrier access, technology, payments, customer care, compliance and daily operations from platforms it developed and an operations center and NOC it runs. The Company also owns LinkUp Mobile, its own prepaid wireless brand, and operates SurgePays POS, which handles retail sales and payments for wireless companies at neighborhood stores. SurgePays brings affordable wireless service and prepaid financial products to consumers through partners and neighborhood stores. For more information, please visit www.surgepays.com.
Forward Looking Statements
This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include, without limitation, statements regarding the launch, adoption and performance of NILwireless, the rollout of school branded wireless services, amounts expected to be paid to schools and programs, and other statements that are not historical facts. Forward looking statements are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results to differ materially. Factors that could cause actual results to differ include, without limitation, the Company’s ability to attract and retain subscribers, the willingness of schools and programs to launch branded services, the Company’s dependence on carrier and payment relationships, regulatory developments affecting wireless services and college athletics, competitive dynamics in prepaid wireless, and the additional risk factors described in the Company’s filings with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward looking statements speak only as of the date of this release. The Company disclaims any obligation to update forward looking statements, except as required by law.
Investor Relations Contact
SurgePays, Inc.
ir@surgepays.com
- Positive interim clinical results from the ongoing BB-301 Phase 1b/2a study for dysphagic patients with Oculopharyngeal Muscular Dystrophy (OPMD), presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients
- BB-301 pivotal study design to be finalized in the first calendar quarter of 2027, and the company remains on track to begin the pivotal trial in mid-2027
- Well-capitalized with cash, as of September 30, 2026, of approximately $176 million
- Benitec plans to transition its fiscal year-end for financial reporting from June 30 to December 31. In this release, operational and program guidance is presented on a calendar-year (CY) basis, and financial guidance is presented on a June 30 fiscal-year (FY) basis
HAYWARD, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage biotechnology company developing disease-modifying genetic medicines for life-threatening, genetically defined diseases, based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its first fiscal quarter ended September 30, 2026, and provided an update on recent clinical data presentations.
“This has been a productive period of continued clinical progress for BB-301,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “We recently attended ESGCT and presented the interim clinical results for the three patients enrolled in Cohort 2 and the full clinical results for the six patients enrolled in Cohort 1 that have completed the 12-month study follow-up period. The consistency and durability of the clinical benefit observed to date continues to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia. We are grateful to the patients, families and investigators who have enabled this progress, and we look forward to confirming the pivotal study design in the first calendar quarter of 2027, with the study on track to commence in mid-2027.”
Clinical Highlights
The Company continues to advance BB-301 through clinical development in the ongoing Phase 1b/2a Clinical Study evaluating the safety and clinical efficacy of locally-administered BB-301 for the treatment of OPMD-related dysphagia.
Positive interim clinical results, presented as a late-breaking poster at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in Hamburg, Germany on October 28, 2026, showed a 100% responder rate across all Cohort 1 (low dose) and Cohort 2 (high dose) patients. There have been no Serious Adverse Events in any patient treated with BB-301 to date.
Financial Highlights
First Quarter 2027 FY Financial Results
Total expenses for the quarter ended September 30, 2026, were $14.5 million compared to $9.8 million for the quarter ended September 30, 2025. The Company incurred $8.6 million of research and development expenses compared to $3.4 million for the comparable quarter ended September 30, 2025. Research and development expenses relate primarily to ongoing clinical development of BB-301 for the treatment of OPMD. General and administrative expenses were $5.9 million compared to $6.4 million for the quarter ended September 30, 2025.
Net loss for the quarter ended September 30, 2026, was $12.9 million compared to a loss of $9.0 million for the quarter ended September 30, 2025. Net loss per basic and diluted share was $(0.26) for the quarter ended September 30, 2026 compared to $(0.22) for the quarter ended September 30, 2025. As of September 30, 2026, the Company had $176.5 million in cash and cash equivalents.
Change in Fiscal Year to Calendar Year
The Company also announced today that it plans to change its existing fiscal year-end from June 30 to December 31 commencing with its first periodic report following the Form 10-Q for the fiscal quarter ended September 30, 2026. In this press release, operational and program guidance is presented on a calendar-year (CY) basis, and historical financial guidance is presented on a June 30 fiscal-year (FY) basis.
About BB-301
BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. BB-301 is administered locally, in a one-time procedure, to the muscles in the throat that drive the swallowing process, an approach designed to maximize local benefit and minimize systemic exposure. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by slowing or halting mutant PABPN1 expression while simultaneously providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA and is currently being evaluated in a Phase 1b/2a, first-in-human, open-label dose escalation study to evaluate the safety and clinical activity of intramuscular doses of BB-301 administered to subjects with OPMD (NCT06185673).
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company developing disease-modifying genetic medicines designed to improve the lives of people with life-threatening, genetically defined diseases. The company’s proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform combines RNA interference, or RNAi, with gene therapy to create medicines designed to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes that restore normal cellular function following a single administration. The company’s lead investigational candidate, BB-301, is the first and only disease-modifying genetic medicine in clinical development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia. For additional information, visit www.benitec.com.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1993, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of preclinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel adeno-associated viral (AAV) vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of DNA-directed RNA interferences (ddRNAi) and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the U.S. Food and Drug Administration and other governmental authorities; regulatory developments in the United States of America; our ability to protect and enforce our patents and other intellectual property rights; our dependence on our relationships with our collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of our collaboration partners; the acceptance of our products and the products of our collaboration partners in the marketplace and market competition; reliance on third-party manufacturers and suppliers, and the risks associated with manufacturing complexity, supply interruptions, and compliance with current good manufacturing practices; sales, marketing and distribution requirements for our product candidates; greater than expected expenses, including expenses relating to litigation or strategic activities; our incurrence of significant losses and the uncertainty of our ability to achieve or sustain profitability or generate any revenue; our ability to satisfy its capital needs through increasing revenue and obtaining additional financing; the impact of local, regional, national and international economic conditions and events, including geopolitical instability, and risks associated with conducting business and seeking regulatory approvals in international markets; our ability to attract and retain key management, scientific, and technical personnel; cyber-security threats and vulnerabilities in our and our third parties’ information technology systems; the impact of legislative and regulatory reforms affecting drug pricing and reimbursement, including Medicare drug-price negotiation and government pricing frameworks; potential product liability claims arising from the use of our product candidates in clinical trials or following any future marketing approval; physicians, patients, third-party payers, or others in the medical community may not be receptive to our product candidates, and we may not generate any future revenue from the sale or licensing of our product candidates; and disruptions to U.S. government agency operations, including FDA staffing changes; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Relations Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com
Media Relations Contact:
Audra Friis
Sam Brown Healthcare Communications
(917) 519-9577
audrafriis@sambrown.com
Source: Benitec Biopharma Inc.
| BENITEC BIOPHARMA INC. Consolidated Balance Sheets (in thousands, except par value and share amounts) (Unaudited) |
||||||||
| September 30, 2026 |
June 30, 2026 |
|||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 176,368 | $ | 179,972 | ||||
| Restricted cash | 114 | 114 | ||||||
| Trade and other receivables | — | 4 | ||||||
| Prepaid and other assets | 1,622 | 1,595 | ||||||
| Total current assets | 178,104 | 181,685 | ||||||
| Property and equipment, net | 110 | 178 | ||||||
| Deposits | 55 | 55 | ||||||
| Prepaid and other assets | 244 | 12 | ||||||
| Right-of-use assets | 585 | 693 | ||||||
| Total assets | $ | 179,098 | $ | 182,623 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Trade and other payables | $ | 7,962 | $ | 4,295 | ||||
| Accrued employee benefits | 608 | 553 | ||||||
| Lease liabilities, current portion | 507 | 496 | ||||||
| Total current liabilities | 9,077 | 5,344 | ||||||
| Other long-term liabilities | 239 | — | ||||||
| Lease liabilities, less current portion | 135 | 266 | ||||||
| Total liabilities | 9,451 | 5,610 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.0001 par value—5,000,000 shares authorized; no shares issued or outstanding at September 30, 2026 and June 30, 2026, respectively | — | — | ||||||
| Common stock, $0.0001 par value—160,000,000 shares authorized; 34,889,313 and 34,416,834 shares issued and outstanding at September 30, 2026 and June 30, 2026 respectively | 4 | 3 | ||||||
| Additional paid-in capital | 457,237 | 451,695 | ||||||
| Accumulated deficit | (286,647 | ) | (273,722 | ) | ||||
| Accumulated other comprehensive loss | (947 | ) | (963 | ) | ||||
| Total stockholders’ equity | 169,647 | 177,013 | ||||||
| Total liabilities and stockholders’ equity | $ | 179,098 | $ | 182,623 | ||||
| BENITEC BIOPHARMA INC. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) |
||||||||
| Three Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses: | ||||||||
| Research and development | 8,618 | 3,370 | ||||||
| General and administrative | 5,859 | 6,433 | ||||||
| Total operating expenses | 14,477 | 9,803 | ||||||
| Loss from operations | (14,477 | ) | (9,803 | ) | ||||
| Other income (loss): | ||||||||
| Foreign currency transaction gain (loss) | (23 | ) | (89 | ) | ||||
| Interest income, net | 1,576 | 1,011 | ||||||
| Other expense, net | (1 | ) | (84 | ) | ||||
| Total other income, net | 1,552 | 838 | ||||||
| Net loss | $ | (12,925 | ) | $ | (8,965 | ) | ||
| Other comprehensive income: | ||||||||
| Unrealized foreign currency translation gain (loss) | 16 | 89 | ||||||
| Total other comprehensive income (loss) | 16 | 89 | ||||||
| Total comprehensive loss | $ | (12,909 | ) | $ | (8,876 | ) | ||
| Net loss | $ | (12,925 | ) | $ | (8,965 | ) | ||
| Net loss per share: | ||||||||
| Basic and diluted | $ | (0.26 | ) | $ | (0.22 | ) | ||
| Weighted average number of shares outstanding: | ||||||||
| Basic and diluted | 49,487,369 | 41,521,280 | ||||||
First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment
New translational data expanded SIL204’s profile, including a coordinated immune-sensitization signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism that supports systemic administration
Third quarter financings increased cash and cash equivalents to $4.8 million and shareholders’ equity to $3.0 million as of September 30, 2026
Grand Cayman, Cayman Islands, Nov. 13, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced financial results for the three-month and nine-month periods ended September 30, 2026, and provided a business update.
Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented: “In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September. At the same time, our laboratory work continued to strengthen the case for SIL204, with new data suggesting it may help the immune system recognize cancer cells, and showing that it uses natural carriers in the blood to enter cancer cells. Our focus now is on enrolling the first group of patients and bringing more hospitals in Israel and Germany into the trial.”
Mirit Horenshtein Hadar, Chief Financial Officer of Silexion, added: “During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market facility, increasing our cash and cash equivalents to $4.8 million and shareholders’ equity to approximately $3.0 million as of September 30, 2026. This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll patients in the Phase 2/3 trial.”
Recent Milestones & Business Highlights
First Patient Dosed in Phase 2/3 Clinical Trial of SIL204: On July 29, 2026, Silexion initiated its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (“LAPC”) at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), and on September 30, 2026, announced that the first patient worldwide had been dosed at TASMC. The prospective, randomized, controlled, multinational, open-label Phase 2/3 study is evaluating SIL204 in combination with standard-of-care chemotherapy, versus chemotherapy alone, in newly diagnosed, treatment-naïve patients with unresectable Stage 3 LAPC whose tumors harbor a confirmed KRAS mutation. SIL204 is administered via a dual-route regimen combining direct EUS-guided intratumoral delivery to the primary tumor with subcutaneous injections designed to provide systemic exposure. The study is structured as an initial safety run-in cohort of approximately 18 patients, followed by expansion into a randomized cohort of approximately 166 patients.
Clinical Site Expansion in Israel and Germany: In Israel, following the approval of the Israeli Ministry of Health, TASMC was activated as the trial’s first clinical site in July 2026, and the first patient was dosed there on September 30, 2026. Additional Israeli oncology centers, alongside leading academic medical institutions in Germany, are progressing through site activation and are expected to join the trial in the coming months.
Expanded Translational Profile of SIL204: In August 2026, Silexion reported preclinical findings showing statistically significant upregulation of FAS (CD95), an immune “death receptor,” and downregulation of HLA-G, an established immune checkpoint, in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines. Together with the MHC-I upregulation reported in May 2026, the findings support a coordinated immune-sensitization signature across three immune pathways and four KRAS mutations (G12D, G12V, G12C and G12R), reinforcing the scientific rationale for combining SIL204 with anti-PD-(L)1 checkpoint inhibitor therapies. In September 2026, the Company reported that SIL204 uses naturally circulating lipoproteins to enter cancer cells and silence mutant KRAS without synthetic transfection reagents or artificial carriers, supporting the systemic administration of SIL204. Pharmacokinetic, cellular uptake kinetics and biodistribution studies are ongoing.
Financing Activities: During the third quarter, Silexion completed a registered public offering in August 2026 with gross proceeds of approximately $2.5 million and a warrant inducement transaction in September 2026 with gross proceeds of approximately $0.84 million, and continued sales of ordinary shares under its at-the-market facility for gross proceeds of approximately $1.9 million. Subsequent to quarter end, on November 10, 2026, the Company effected a 1-for-24 reverse share split.
Financial Results for the Three Months Ended September 30, 2026
Research and development (“R&D”) expenses for the three months ended September 30, 2026, were approximately $1.3 million, compared to approximately $2.2 million for the three months ended September 30, 2025, a decrease of 40.9%.
General and administrative (“G&A”) expenses for the three months ended September 30, 2026, were approximately $1.4 million, compared to approximately $1.1 million for the three months ended September 30, 2025, an increase of 27.3%.
Net loss for the three months ended September 30, 2026, was approximately $2.5 million, compared to approximately $3.3 million for the three months ended September 30, 2025, a decrease of 24.2%.
Financial Results for the Nine Months Ended September 30, 2026
R&D expenses for the nine months ended September 30, 2026, were approximately $4.9 million, compared to approximately $3.8 million for the nine months ended September 30, 2025, an increase of 28.9%. The increase related to the operational ramp-up for the Phase 2/3 clinical trial of SIL204.
G&A expenses for the nine months ended September 30, 2026, were approximately $4.2 million, compared to approximately $3.5 million for the nine months ended September 30, 2025, an increase of 20.0%.
Net loss for the nine months ended September 30, 2026, was approximately $8.8 million, compared to approximately $7.5 million for the nine months ended September 30, 2025, an increase of 17.3%. The increase was mainly due to higher R&D expenses related to the Phase 2/3 clinical trial of SIL204.
Balance Sheet Highlights
- As of September 30, 2026, Silexion had cash and cash equivalents of $4.8 million, compared to $6.0 million as of December 31, 2025, and $2.2 million as of June 30, 2026.
- Total shareholders’ equity was $3.0 million as of September 30, 2026, compared to $2.6 million as of December 31, 2025.
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication are forward-looking statements, including, for example, statements regarding the development of SIL204; the conduct, enrollment and timing of the ongoing Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, including enrollment of the safety run-in cohort and expansion into a randomized cohort; the timing of activation of additional clinical trial sites in Israel and Germany and the potential expansion of the trial into additional jurisdictions; the timing and results of ongoing translational, pharmacokinetic, cellular uptake and biodistribution studies, and the potential to evaluate SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies; the potential therapeutic benefits, mutation coverage, mechanism of action and clinical utility of SIL204 across KRAS-driven cancers; Silexion’s business strategy and development plans; Silexion’s ability to raise additional capital and its future capital requirements, including through its at-the-market facility, public and private offerings, warrant exercises, warrant inducement transactions and other financing arrangements; the outcome of litigation; and Silexion’s ability to restore and maintain compliance with Nasdaq continued listing requirements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the degree of success of Silexion’s ongoing and planned clinical trials, including the Phase 2/3 clinical trial of SIL204, and the risk that early observations may not be predictive of later results; (ii) Silexion’s ability to enroll and treat patients, and to complete the activation of additional clinical sites, on anticipated timelines; (iii) whether Silexion is able to successfully execute upon its strategy and plans via its future operations, and maintain a positive financial position; (iv) the impact of the regulatory environment and compliance complexities; (v) whether Silexion is able to develop future partnerships or other relationships with third parties; (vi) Silexion’s future capital requirements and sources and uses of cash, and the potential impact on the Company’s operations of any inability to secure such capital; (vii) the substantial doubt about the Company’s ability to continue as a going concern described in Note 1(e) to the Company’s unaudited condensed consolidated financial statements for the three-month and nine-month periods ended September 30, 2026; (viii) whether Silexion succeeds at maintaining its Nasdaq listing, including the determination of the Nasdaq hearings panel, compliance with the shareholders’ equity and minimum bid price requirements, and any potential increase to the market value of listed securities requirement; and (ix) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 12, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
info@silexion.com
Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share and per share data)
| September 30, | December 31, | |
| 2026 | 2025 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $4,760 | $5,991 |
| Restricted cash | 28 | 27 |
| Prepaid expenses | 1,221 | 570 |
| Other current assets | 102 | 49 |
| TOTAL CURRENT ASSETS | 6,111 | 6,637 |
| NON-CURRENT ASSETS: | ||
| Restricted cash | 61 | 57 |
| Long-term deposit and other non-current assets | 320 | 84 |
| Property and equipment, net | 21 | 25 |
| Operating lease right-of-use asset | 314 | 412 |
| TOTAL NON-CURRENT ASSETS | 716 | 578 |
| TOTAL ASSETS | $6,827 | $7,215 |
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (continued)
(U.S. dollars in thousands, except share and per share data)
| September 30, | December 31, | |
| 2026 | 2025 | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Trade payables | $1,244 | $787 |
| Current maturities of operating lease liability | 196 | 182 |
| Employee related obligations | 460 | 879 |
| Other account payable | 1,781 | 910 |
| Private warrants to purchase ordinary shares (including $* due to related party, as of September 30, 2026 and December 31, 2025) | * | * |
| TOTAL CURRENT LIABILITIES | 3,681 | 2,758 |
| NON-CURRENT LIABILITIES: | ||
| Long-term operating lease liability | 178 | 286 |
| Related Party Promissory Note | – | 1,568 |
| TOTAL NON-CURRENT LIABILITIES | $178 | $1,854 |
| TOTAL LIABILITIES | $3,859 | $4,612 |
| SHAREHOLDERS’ EQUITY: | ||
| Ordinary shares ($3.24 par value per share, 662,500 and 37,500 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 603,055 and 13,028 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively) | 1,954 | 42 |
| Additional paid-in capital | 64,997 | 57,727 |
| Accumulated deficit | (63,983) | (55,166) |
| TOTAL SHAREHOLDERS’ EQUITY | $2,968 | $2,603 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $6,827 | $7,215 |
All share amounts, and par value per share, reflect a 1-for-10 reverse share split effected on May 28, 2026, and a 1-for-24 reverse share split effected on November 10, 2026, as described in Notes 1(d) and 13 to the Company’s condensed consolidated financial statements included in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2026.
* Represents an amount less than $1 thousand.
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except share and per share data)
| Nine months ended September 30, | Three months ended September 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| OPERATING EXPENSES: | ||||
| Research and development (including $176 and $0 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $0 from related party for the three-month periods ended September 30, 2026 and 2025) | $4,868 | $3,765 | $1,286 | $2,157 |
| General and administrative (including $298 and $96 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $16 and $38 from related party for the three-month periods ended September 30, 2026 and 2025, respectively) | 4,245 | 3,461 | 1,398 | 1,135 |
| TOTAL OPERATING EXPENSES | 9,113 | 7,226 | 2,684 | 3,292 |
| OPERATING LOSS | 9,113 | 7,226 | 2,684 | 3,292 |
| Financial expenses (income), net (including $(307) and $203 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $(138) and $(26) from related party for the three-month periods ended September 30, 2026 and 2025, respectively) | (296) | 271 | (151) | (30) |
| LOSS BEFORE INCOME TAX | $8,817 | $7,497 | $2,533 | $3,262 |
| INCOME TAX | * | 3 | * | – |
| NET LOSS | $8,817 | $7,500 | $2,533 | $3,262 |
| LOSS PER SHARE, BASIC AND DILUTED | $115.56 | $2,486.20 | $13.70 | $691.14 |
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE** | 76,305 | 3,017 | 184,927 | 4,720 |
* Represents an amount less than $1 thousand.
** All share and per share amounts reflect (for periods preceding the relevant reverse share split, on a retroactive basis) the 1-for-10 reverse share split effected on May 28, 2026 and the 1-for-24 reverse share split effected on November 10, 2026, as described in Notes 1(d) and 13 to the Company’s condensed consolidated financial statements included in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2026.
BEND, Ore., Nov. 13, 2026 (GLOBE NEWSWIRE) — BranchOut Food Inc. (Nasdaq: BOF) (“BranchOut” or the “Company”), a food technology company producing fruit, vegetable, and dairy-based snacks and ingredients through its REV dehydration technology, today announced that it will host a conference call and webcast to review its third quarter 2026 financial results and provide a corporate and shareholder update.
The call will be held on Monday, November 16, 2026, at 4:30 PM Eastern Time and will feature prepared remarks from Eric Healy, Chief Executive Officer, and John Dalfonsi, Chief Financial Officer, followed by a question-and-answer session.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Date: November 16, 2026
Time: 4:30 p.m. Eastern time
Toll & Toll Free: 877-407-9039 / 201-689-8470
Live Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1783131&tp_key=21386c42a3
Conference Call Replay Information
The replay will be available beginning approximately 1 hour after the completion of the live event.
Toll & Toll free: 844-512-2921 / 412-317-6671
Access ID: 13763869
Replay Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1783131&tp_key=21386c42a3
About BranchOut Food Inc.
BranchOut Food is a leading international food technology company, specializing in the production of high-quality dehydrated fruit and vegetable-based products through its REV Technology. This next-generation dehydration method preserves up to 95% of the original nutrition of fresh produce, offering superior quality and taste. Protected by over 17 patents, BranchOut’s technology enables it to stand out as a trusted brand, ingredient and a private-label supplier. For more information, visit www.branchoutfood.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “position,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of BranchOut Food, Inc., (the Company) strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
Investor Contacts
Brett Maas, Hayden IR, (646) 536-7331, brett@haydenir.com
James Carbonara, Hayden IR, (646) 755-7412, james@haydenir.com
